R Squared Ltd Acquires 1,076 Shares of IDEXX Laboratories, Inc. $IDXX

R Squared Ltd acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 1,076 shares of the company’s stock, valued at approximately $562,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDXX. Arlington Trust Co LLC increased its holdings in shares of IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after acquiring an additional 19 shares in the last quarter. Bell Investment Advisors Inc lifted its holdings in shares of IDEXX Laboratories by 45.5% during the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock valued at $33,000 after purchasing an additional 20 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC grew its position in shares of IDEXX Laboratories by 21.4% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock valued at $67,000 after purchasing an additional 21 shares during the period. Valeo Financial Advisors LLC grew its position in shares of IDEXX Laboratories by 6.4% in the 2nd quarter. Valeo Financial Advisors LLC now owns 383 shares of the company’s stock valued at $202,000 after purchasing an additional 23 shares during the period. Finally, Meeder Advisory Services Inc. increased its stake in IDEXX Laboratories by 1.3% during the 1st quarter. Meeder Advisory Services Inc. now owns 1,896 shares of the company’s stock worth $1,066,000 after purchasing an additional 25 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on IDXX. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Barclays reduced their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. KeyCorp began coverage on IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating for the company. Finally, The Goldman Sachs Group assumed coverage on IDEXX Laboratories in a report on Friday, October 16th. They set a “buy” rating and a $740.00 target price for the company. Seven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $717.27.

IDEXX Laboratories Trading Down 0.7%

NASDAQ IDXX opened at $698.02 on Friday. The stock has a market capitalization of $55.00 billion, a price-to-earnings ratio of 47.07 and a beta of 1.55. The stock’s 50 day moving average price is $558.91 and its two-hundred day moving average price is $573.47. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.88 and a current ratio of 1.19. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same period last year, the business earned $3.22 EPS. The business’s quarterly revenue was up 9.9% on a year-over-year basis. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jonathan Mazelsky sold 25,140 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $703.19, for a total transaction of $17,678,196.60. Following the completion of the sale, the insider owned 83,803 shares in the company, valued at $58,929,431.57. The trade was a 23.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 41,428 shares of company stock valued at $28,567,934 in the last three months. 0.79% of the stock is currently owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.